Kornimate/medical-research-clean huggingface dataset:
a comparison of european and chinese blood sugar responses

Conditions: Diabetes

Summary: this study is designed to compare the responses to an oral glucose challenge between people of european and chinese heritage (essential participants in the european arm must have tow european parents and likewise for the chinese participants).

100 participants (50 european and 50 chinese) will attend a lab after an overnight fast and have a capillary finger-prick blood test to assess fasted blood glucose levels and then consume a 50 gram glucose solution. blood test will be repeated at 15, 30, 45, 60, 90 and 120 minutes post consumption of the glucose solution. this test will be repeated on a spate occasion at least a week later than the first test. participants will only take part in the experiment after singing informed consent and agreeing to take part in the study and after a medical screening questionnaire assessing that they are non-diabetic or haemophiliac or have blood born infections.

Eligibility criteria:
inclusion criteria: * european ethnicity * chinese ethnicity * age 19-59 years exclusion criteria: * diabetics * serious blood born infection * haemophilia
microbiological evaluation of single versus multiple visits regeneration using maldi-tof mass spectrometry

Conditions: Pulp Necroses; Tooth, Nonvital

Summary: aim of the study is to assess canal disinfection using matrix assisted laser desorption ionization-time of flight mass spectrometry (maldi-tof ms) in single visit and multiple visit regeneration protocols, and to assess clinical and radiographic outcomes of single visit and multiple visit regeneration protocols.

thirty patients with necrotic immature permanent teeth showing periapical lesions will be randomly divided in two groups: group (1) single visit regeneration and group (2) multiple visits regeneration protocol, in which calcium hydroxide will be applied for one week or more according to resolution of signs and symptoms. dentin debris collected on a file will be taken as microbiologic sample to be cultured and examined by maldi-tof ms. this will be performed after the access cavity preparation and after irrigation in both groups, these samples will be labelled a and b, respectively. in group (2) there will be a third sample labeled c which will be taken after the removal of the intra canal calcium hydroxide.

Eligibility criteria:
inclusion criteria: * immature permanent upper anterior teeth. * necrotic teeth confirmed by sensibility test. * teeth with periapical lesions confirmed by periapical radiograph using paralleling device. exclusion criteria: * teeth with orthodontic wires or brackets. * patient with history of allergy to any medication. * patient with history of bleeding disorders. * patient with medical illness or taking medications.
a relevance study between the result of clinical drug intervention and next-generation sequencing technology focused on refractory helicobacter pylori infection

Conditions: Gastritis

Summary: approximately 50% of people in the world are infected with h. pylori, and its eradication rate fail to exceed 80% and even fails into an unacceptable range.various risk factors for infection include lower socioeconomic status, younger age, and geographic location.in the present study, investigators aimed to perform a prevalence survey about risk factors for h. pylori infection.to obtain the higher eradication of h. pylori and find out the relevance between the diverse infection and clinical drug focused on refractory h. pylori infection.


Eligibility criteria:
inclusion criteria: 1. age 18\~70 years old, male or female, untreated patients. 2. symptoms of abdominal pain, bloating, acid reflux,belching,nausea,vomiting,heartburn, chest pain, vomiting, melena, etc. 3. unused antibiotics, bismuth, h2 receptor antagonists or ppi by nearly 4 weeks 4. 13c-labelled urea breath test positive. 5. agreed to helicobacter pylori culture and sensitivity testing taken by endoscopy gastric biopsy specimens,and the result of culture was positive. 6. agreed to helicobacter pylori eradication therapy and cooperate with the eradication efficacy follow-up survey. exclusion criteria: 1. severe heart, liver, kidney dysfunction. 2. pregnant or lactating women. 3. complications of bleeding, perforation, pyloric obstruction, cancer. 4. esophageal,gastrointestinal surgery history. 5. patients can not properly express their complaints,such as psychosis, severe neurosis. 6. taking nsiad or alcohol abusers. 7. allergic to penicillin or either drugs of the 6 antibiotic tested by susceptibility testing.

Keywords: helicobacter pylori antibiotic resistance sequencing
comparing the efficacy of hybrid, high-dose dual and bismuth quadruple therapies

Conditions: Helicobacter Pylori Infection

Summary: both hybrid and high-dose dual therapies developed by the scholars from taiwan can achieve a high eradication rate for clarithromycin-resistant strains, and have a great potential to replace bismuth quadruple therapy in the treatment of h. pylori infection.

bismuth quadruple therapy has been recommended as a choice of the first-line treatment for h. pylori infection in several important international consensuses. however, it is associated with a high frequency of adverse events. both hybrid and high-dose dual therapies developed by the scholars from taiwan can achieve a high eradication rate for clarithromycin-resistant strains, and have a great potential to replace bismuth quadruple therapy in the treatment of h. pylori infection. in the second-line treatment, tetracycline-levofloxacin quadruple therapy developed by our study group can achieve a higher eradication rate than levofloxacin triple therapy for salvage treatment of hybrid therapy. however, whether the new therapy can be a promising rescue treatment for bismuth quadruple or high-dose dual therapy remains unanswered.

Eligibility criteria:
inclusion criteria: * consecutive h pylori-infected outpatients, at least 20 years of age, with endoscopically proven peptic ulcer diseases or gastritis exclusion criteria: * previous h pylori-eradication therapy * ingestion of antibiotics or bismuth within the prior 4 weeks * patients with allergic history to the medications used * patients with previous gastric surgery * the coexistence of serious concomitant illness (for example, decompensated liver cirrhosis, uremia) * pregnant women

Keywords: helicobacter pylori eradication rate
comparison of insulin detemir versus insulin nph on weight change in overweight and obese with type 2 diabetes

Conditions: Diabetes; Diabetes Mellitus, Type 2

Summary: this trial is conducted in europe. the purpose of the trial is to investigate the effect of insulin detemir on weight change in overweight and obese patients with type 2 diabetes.


Eligibility criteria:
inclusion criteria: * hba1c: 7.5-11.0% * bmi: 25-40 kg/m2 exclusion criteria: * treatment with any oad (oral antidiabetic drugs) except metformin
tess shoulder arthroplasty data collection

Conditions: Arthritis

Summary: this observational study intends to collect efficacy and safety data on tess shoulder system

the t.e.s.s.® shoulder system has been developed to provide a complete solution for all the indications for shoulder arthroplasty, arthritis, rotator cuff arthropathy, proximal humeral fracture, minimising bone resection and restoring the natural anatomy of the patient.

Eligibility criteria:
inclusion criteria: * a pre-operative level of pain and function the same as for conventional joint replacement * a likelihood of obtaining relief of pain and improved function * full skeletal maturity * ability to follow instructions * good general health for age * willing to return for follow-up evaluations exclusion criteria: * glenohumeral joint infection, osteomyelitis * neuro-muscular complications * inability to co-operate with and complete the study
the hemodynamic response to prolonged dobutamine infusion

Conditions: Healthy; Heart Failure

Summary: a decrease in the response of beta 1 adrenergic receptors to agonists (desensitization) is thought to play a major role in the pathogenesis of diseases such as congestive heart failure. however, currently, there is no in vivo model that will enable us to measure desensitization of the hemodynamic responses to beta 1 adrenergic receptors in vivo. our hypothesis is that constant 3 hours intravenous infusion of the selective beta1 adrenergic receptor agonist dobutamine will result in gradual decline in hemodynamic responses to dobutamine over time.


Eligibility criteria:
inclusion criteria: * healthy subjects exclusion criteria: * consumption of any medications during the 2 weeks prior to the study * history of chest pain or tachycardia

Keywords: desensitization beta adrenergic receptors healthy subjects
cannabidiol oral solution in pediatric participants with treatment-resistant seizure disorders

Conditions: Seizures

Summary: this is a phase 1/2, open-label trial designed to assess the pharmacokinetics, safety, tolerability, and preliminary efficacy of 3 multiple ascending doses of cannabidiol oral solution in a sequential fashion. participants will be pediatric (aged 1-17, inclusive), experiencing treatment-resistant seizures, and satisfy all inclusion/exclusion criteria.


Eligibility criteria:
inclusion criteria: * meets protocol-specified criteria for qualification and contraception, including treatment-resistant seizure disorder * is able to speak and understand the language in which the study is being conducted, is able to understand the procedures and study requirements and has voluntarily signed and dated an informed consent form approved by the institutional review board before the conduct of any study procedure * in the opinion of the investigator, the participants and parent(s)/caregiver(s) are willing and able to comply with the study procedures and visit schedules, including venipuncture, inpatient stay at the study center, dosing at the study center twice a day as needed while an outpatient), and the follow-up visits (if applicable) exclusion criteria: * participant or parent(s)/caregiver(s) have daily commitments during the study duration that would interfere with attending all study visits * history or current use of dietary supplements, drugs or over-the counter medications outside protocol-specified parameters * signs, symptoms or history of any condition that, per protocol or in the opinion of the investigator, might compromise: 1. the safety or well-being of the participant or study staff 2. the safety or well-being of the participant's offspring (such as through pregnancy or breast-feeding) 3. the analysis of results

Keywords: treatment-resistant seizures
combined resistance and aerobic exercise training on obesity in adolescent girls

Conditions: Obesity

Summary: the purpose of the study was to observe therapeutic effects of combined resistance and aerobic exercise training (crae) on hyperinsulemia in obese adolescent girls. forty obese adolescent girls (14±1 years) participated in this study. the participants were randomly separated into two groups; no-exercise group (n=20) and exercise group (n=20). the exercise group performed 12 weeks of crae.


Eligibility criteria:
inclusion criteria: * obese with hyperinsulinemia * obese with abdominal obesity exclusion criteria: * hypertension * pregnancy * chronic diseases * weight loss diet within the last 6 months
lumbar puncture stylet technique in children

Conditions: Traumatic Tap

Summary: lumbar puncture (lp) is a procedure performed frequently among children in the emergency department (ed). although it has been performed for decades, and for distinct indications, the technique itself can often lead to traumatic results, which can complicate its interpretation and lead to over-treatments and hospitalizations. several factors have been suggested to improve the success rate of lps. among them, the stylet-out (so), also known as the early stylet removal technique, has been suggested but not properly studied. the aim of this study is to evaluate whether the stylet-out technique can reduce the probability of failure or traumatic lumbar puncture procedures in a pediatric population presenting to the emergency department as compared to the standard stylet-in (si) approach. to achieve this goal, the investigator will conduct a randomized controlled trial comparing the so versus si techniques in a tertiary care, pediatric, university-affiliated emergency. all children younger than 18 years of age requiring a lp as part of their ed workup will be eligible and randomized to either the standard si or so group. the primary outcome will be the first-attempt lp success rate as defined by the minimum amount of cerebrospinal fluid (csf) necessary to perform a leukocyte count and bacterial/viral csf cultures, according to each laboratory with red blood cell count \< 1000/mm3. secondary outcomes will include the following: overall lp success rate (i.e. despite number of attempts), proportion of traumatic lp, number of lp attempts, number of changes in providers performing the lp, proportion of traumatic lp, total time to procedure, mean difference in pain scores and satisfaction rates in both groups. the hypothesis is that the use of the stylet out approach will reduce the number of failed and traumatic lp in the pediatric population presenting to the ed as compared to the standard si approach.


Eligibility criteria:
inclusion criteria: * all patients younger than 18 years of age (no minimal age) * all patients who require a diagnostic lumbar puncture as part of their emergency department workup exclusion criteria: * patients with lumbar puncture contraindications * parents/patients unable to give consent * patients who have had a traumatic of failed lumbar puncture prior to the emergency department transfer

Keywords: lumbar puncture stylet-in stylet-out children emergency department
glucagon-like peptide 2 - a glucose dependent glucagonotropic hormone?

Conditions: Glucose Metabolism Disorders; Endocrine or Metabolic Disease

Summary: infusion of glucagon-like peptide 2 (glp-2) during euglycaemia, hypoglycaemia and hyperglycaemia and evaluation of the effect on glucagon secretion in healthy subjects.

this is a cross-over, randomized, double-blinded study in which 10 participants will undergo 6 experimental days each. the participants will have their plasma glucose clamped at either euglycaemia (fasting level), hypoglycemia (2,5 mmol/l) or hyperglycemia (10 mmol/l) during infusion of glp-2 or saline (placebo) the six days will be as follows: * euglycaemia + placebo * euglycaemia + glp-2 * hyperglycaemia + placebo * hyperglycaemia + glp-2 * hypoglycaemia + placebo * hypoglycaemia + glp-2 the primary endpoint will be levels of plasma glucagon. secondary endpoint will be levels of glp-1, glp-2, insulin/c-peptide, oxm, amino acids, cck, gastrin, norepinephrine, bile acids, fgf-19/fgf-21. secondary endpoints will also include ultrasound scan of the gallbladder.

Eligibility criteria:
inclusion criteria: * caucasian ethnicity * body mass index (bmi): 18.5-27 kg/m2 * glycated haemoglobin (hba1c) \< 42 mmol/mol * normal haemoglobin (8.3-10.5 mmol/l) * informed and oral and written consent exclusion criteria: * prediabetes, type 1 diabetes or type 2 diabetes or first-degree relatives with type 1 or type 2 diabetes * nephropathy (egfr \< 60 and/or albuminuria) * known liver disease and/or alanine transaminase (alat) or aspartate transaminase (asat) \> 2 × upper normal limit * bilirubin \> 25 μmol/l * known intestinal disease or previous surgery of the intestines * active or recent malignant disease * treatment with medicine that cannot be paused for 12 hours * any condition considered incompatible with participation by the investigators

Keywords: glp-2 glucagon
treatment-related benefit and satisfaction in fabry patients. insight in patients expectations and preferences

Conditions: Fabry Disease; Anderson Fabry Disease

Summary: in the shared decision-making process, patients should express their expectations and preferences regarding treatment to the physician. a specific questionnaire addressing needs and expectations of fabry patients has been built at the initiative of amicus. in addition, this questionnaire also evaluates the benefit of treatment from the patient's perspective. nothing is known until now on patient's expectations, potential clustering of patients regarding their expectations and evaluation of treatment benefit from the patients perspective. study objectives are differentiated according to the study phase (inclusion and follow-up). at inclusion, the primary objective is to cluster patients according to their needs and expectations regarding treatment. during follow-up, the primary objective is to evaluate treatment benefit in relation with patients needs and expectations.

prospective, longitudinal, non-comparative, open-label, multicentre, non interventional cohort study.

Eligibility criteria:
inclusion criteria: * patients ≥ 16 years old * diagnosed with fabry disease * with amenable mutation * decision by clinician to start or pursue ongoing ert or migalastat * non-opposition form to participate in the study signed exclusion criteria: - concomitant patient participation in an interventional clinical study (category 1 interventional research or category 2 interventional research according to the jardé law classification in france)
a study to assess the safety and pharmacokinetics of an inhibitor of poly adp-ribose polymerase-1 (parp)

Conditions: Ovarian Neoplasms; BRCA1 Protein; BRCA2 Protein

Summary: to determine the safety, tolerability, dose-limiting toxicity (dlt), pharmacokinetic-pharmacodynamic profile, and maximum tolerated dose (mtd) of ku-0059436 when administered orally to patients with advanced solid tumours. to further evaluate the safety and efficacy of ku-0059436 in an expanded cohort of bcra-enriched population, primarily ovarian cancer patients


Eligibility criteria:
inclusion criteria: * confirmed malignant advanced solid tumour refractory to standard therapy or for which no suitable effective standard therapy exists. exclusion criteria: * anti-cancer therapy including chemotherapy, radiotherapy, endocrine therapy, immunotherapy or use of other investigational agents within the 4 weeks prior to trial entry (or a longer period depending on the defined characteristics of the agents used).

Keywords: advanced ovarian cancer brca 1 protein brca 2 protein poly(adp ribose)polymerases
effect of parenteral iron therapy on inflammatory response and oxidative stress chronic hemodialysis

Conditions: Hemodialysis; Chronic Kidney Disease; Inflammation

Summary: parenteral iron therapy is now commonly administered to dialysis patients with the majority of patients receiving this therapy as part of the treatment for their anemia. although intravenous iron has improved clinical response to recombinant erythropoietin, there is a concern that iron therapy may have deleterious effects in chronic kidney disease (ckd) patients. iron can damage tissues by catalyzing the conversion of hydrogen peroxide to free-radical ions that attack cellular proteins, dna and membranes as part of oxidative stress. numerous in vitro studies have shown tissue toxicity from iron and increased infectious potential. oxidative stress can also lead to activation of the systemic inflammatory response with the release of a number of key cytokines and growth factors. there is now a link between inflammation, oxidative stress and acceleration of vascular disease in both patients with normal as well as reduced renal function. in a study comparing normal versus low hematocrit levels in hemodialysis patients, mortality was higher in the normal hematocrit group. the major difference between the two groups has been attributed to the fact that patients in the normal hematocrit group received significantly more iron than the patients with low hematocrit. there was a 2.4 fold greater mortality rate in patients receiving parenteral iron. the effect of parenteral iron administration on activation of the systemic inflammatory response in hemodialysis patients has not been evaluated. the purpose of this study is to measure a number of key cytokines, inflammatory and oxidative stress markers in hemodialysis patients receiving iron repletion therapy as part of their standard care.

study design patients who have been prescribed iron repletion therapy (100 mg iv every dialysis treatment for ten treatments) by their primary nephrologist will be recruited for the study. baseline blood samples will be obtained before and after each dialysis treatment for two dialysis treatments prior to the administration of iron. on the day of dialysis that iron therapy is started, blood samples will be obtained before and after the dialysis treatment via the patient's vascular access. this procedure will be repeated each dialysis treatment for the ten sessions during which the patient is receiving intravenous iron. subsequently, pre-dialysis blood samples will be obtained every week for four weeks after the administration of intravenous iron has been completed

Eligibility criteria:
inclusion criteria: * hemodialysis patients age 18 or greater who are prescribed parenteral iron by their primary nephrologist